Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) plans to release its financial results for Q1 2023 on Tuesday, May 2, 2023, after trading hours. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Pulmonx is recognized for its innovative treatments for lung diseases, particularly the Zephyr® Endobronchial Valve, which has received FDA pre-market approval as a breakthrough device. The company has successfully deployed over 100,000 valves to treat more than 25,000 patients globally, illustrating its significant market presence and commitment to advancing pulmonary care.

Positive

• Pulmonx's Zephyr Valve has received FDA pre-market approval as a breakthrough device.
• Over 100,000 Zephyr valves have been deployed, showing strong demand.
• The company treats more than 25,000 patients, demonstrating extensive market penetration.

Negative

• None.

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005107/en/

Brian Johnston

Gilmartin Group

investors@pulmonx.com

Source: Pulmonx Corporation

FAQ

When will Pulmonx Corporation announce its Q1 2023 financial results?

Pulmonx Corporation will announce its Q1 2023 financial results on May 2, 2023, after the market closes.

What time is Pulmonx's Q1 2023 conference call?

The conference call to discuss Q1 2023 financial results will start at 1:30 p.m. PT / 4:30 p.m. ET.

What is the significance of the Zephyr Valve for Pulmonx Corporation?

The Zephyr Valve is significant for Pulmonx as it has received FDA pre-market approval and is a key product in treating severe lung diseases.

How many patients have been treated with the Zephyr Valve?

Over 25,000 patients have been treated with the Zephyr Valve, highlighting its extensive use in the market.